REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 20th, 2020 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 16, 2020, is entered into by and between AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Convertible Preferred Stock and Warrant Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement.
COMMON STOCK PURCHASE WARRANT AZURRX BIOPHARMA, INC.Warrant Purchase Agreement • July 20th, 2020 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, [including the Stockholder Approval]1 and the additional limitations set forth in Sections 2(e), at any time [after the earlier of (i) the Stockholder Approval and (ii) the date that is six months from the date hereof]2 (the “Initial Exercise Date”) and on or prior to the close of business on the five-year anniversary of the Issuance Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), up to [_____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in S
CONVERTIBLE PREFERRED STOCK AND WARRANT SECURITIES PURCHASE AGREEMENTConvertible Preferred Stock and Warrant • July 20th, 2020 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
This Convertible Preferred Stock and Warrant Securities Purchase Agreement, dated as of July 16, 2020 (this “Agreement”), is entered into by and among AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), and the other signatories hereto (each an “Investor” and collectively, the “Investor”).
